This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Assessing post-conversion tax brackets involves projecting income, deductions, and future tax rates to decide if a conversion makes sense.
26,029 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Bitcoin and Ethereum options contracts are set to expire Friday, totaling around $2 billion in notional. Analysts exp...
The full text of a U.S.-Iran peace deal is public, triggering market swings and mixed ally responses. This article br...
The Nasdaq 100 ETF is seeing its busiest month in years as traders chase SpaceX exposure, aided by new weighting rule...
PepsiCo deploys another round of price cuts on its snack lineup to lure budget-conscious shoppers as geopolitical ten...
Five senior Democrats publicly accuse Trump of crypto ties, fueling a wider fight over rules for digital assets. Bitc...
Morgan Stanley's latest bottom up view argues that AI infrastructure demand will outpace supply, turning the Nebius s...
SpaceX has dazzled investors, but big bets come with big risks. This article explains three reasons reasons spacex st...
Southeast Asia’s fast-growing hospitality is expanding rapidly, but a persistent labor shortage threatens growth as b...
Oil remains a core part of global energy, and a patient, rules-based approach can reward investors. This article buil...
What could Nu Holdings look like a decade from now? This article breaks down growth catalysts, potential paths, and p...
Lilly shares moved lower after Novo Nordisk announced price cuts on leading obesity drugs, signaling a tougher compet...